Pathologic Bone Resorption and New Bone Formation in Inflammatory Arthritis

• 1. Ritchlin CT
  2. Lubrano E
  3. Chimenti MS
  4. Leibowitz E
  5. Sharaf M
  6. Rampakakis E
  7. Nantel F
  8. Lavie F
  9. Deodhar A
  Guselkumab Efficacy in Biologic-Naïve Participants with Psoriatic Arthritis and Severe Disease Activity: Post Hoc Analysis of a Phase 3 Study.; Rheumatology and therapy. 2025 Jul 21.
• 1. Ritchlin CT
  2. Coates LC
  3. McInnes IB
  4. Mease PJ
  5. Merola JF
  6. Tanaka Y
  7. Asahina A
  8. Gossec L
  9. Gottlieb AB
  10. Warren RB
  11. Ink B
  12. Bajracharya R
  13. Shende V
  14. Coarse J
  15. Landewé RBM
  Corrigendum to Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study Ann Rheum Dis. 2023;82:1404-1414.; Annals of the rheumatic diseases. 2025 Jun 18.
• 1. Garcia-Hernandez ML
  2. Ritchlin CT
  3. Guy DR
  4. Wechalekar M
  New Insights into the Pathogenesis of Psoriatic Arthritis.; Rheumatic diseases clinics of North America; Vol 51(3), pp. 397-415. 2025 Jun 11.
• 1. Mease PJ
  2. Merola JF
  3. Tanaka Y
  4. Gossec L
  5. McInnes IB
  6. Ritchlin CT
  7. Landewé RBM
  8. Asahina A
  9. Ink B
  10. Heinrichs A
  11. Bajracharya R
  12. Shende V
  13. Coarse J
  14. Coates LC
  Summary of Research: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies.; Rheumatology and therapy. 2025 May 10.

May 23, 2025
AIR Research Presented at the 2025 AAI Meeting

May 23, 2025
Dr. Javier Rangel-Moreno Lecturer at the 2025 Course of Biomedicine and Immunology

January 15, 2025
ROChester Stimulating Access to Research during Residency (ROC StARR) Health and Immune Function Across the Lifespan to Begin July 1st

January 6, 2025
Jennifer Anolik Named Chief of Allergy, Immunology and Rheumatology Division

December 13, 2024
Ilana Abeles Receives Clinical Trial Investigator Award

All News »